Allarity Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/30/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $320,000 | $0 | — | — | — |
| Gross profit | — | — | — | -$2.3M | — |
| Research and development | $6.6M | $6.1M | $7.1M | $6.9M | — |
| Operating expenses | $12.9M | $27.2M | $17.1M | $34.5M | — |
| Operating income | -$12.6M | -$27.2M | -$17.1M | -$34.5M | — |
| Interest expense | $185,000 | $653,000 | $498,000 | $223,000 | — |
| Pretax income | -$11.2M | -$24.9M | -$11.8M | -$17.6M | — |
| Income tax expense | $0 | -$381,000 | $83,000 | -$1.5M | — |
| Net income | -$11.2M | -$24.5M | -$11.9M | -$16.1M | — |
| Balance Sheet | |||||
| Cash and equivalents | $14.7M | $19.5M | $166,000 | $2.0M | — |
| Current assets | $17.9M | $22.3M | $2.0M | $5.0M | — |
| Total assets | $18.3M | $22.6M | $11.9M | $14.5M | — |
| Current liabilities | $8.4M | $10.8M | $14.2M | $11.2M | — |
| Total liabilities | $8.4M | $10.8M | $14.6M | $12.7M | — |
| Total debt | — | — | — | $2.7M | $650,000 |
| Stockholders' equity | $9.8M | $11.8M | -$2.8M | -$113,000 | — |
| Cash Flow Statement | |||||
| Cash from operations | -$14.8M | -$17.4M | -$12.7M | -$16.8M | — |
| Depreciation and amortization | — | $9,000 | $37,000 | $60,000 | — |
| Stock-based compensation | $482,000 | $71,000 | $71,000 | $1.8M | — |
| Capital expenditure | $8,000 | $298,000 | $0 | $18,000 | — |
| Free cash flow | -$14.8M | -$17.6M | -$12.7M | -$16.8M | — |
| Share repurchases | $3.2M | $0 | — | — | — |
| Impairments | $0 | $9.7M | $0 | $3.6M | — |
Shares outstanding 15.9M · Free float 46.8%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.